Budoucí P/E společnosti Génomic Vision SA
Jaká je hodnota metriky Budoucí P/E společnosti Génomic Vision SA?
Hodnota metriky Budoucí P/E společnosti Génomic Vision SA je -0.27
Jaká je definice metriky Budoucí P/E?
Budoucí poměr P/E (Forward price to earnings ratio) vyjadřuje poměr současné ceny a odhadovaného zisku na akcii v následujících dvanácti měsících.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Budoucí P/E společností v sektoru Health Care sektor na EURONEXT ve srovnání se společností Génomic Vision SA
Čemu se věnuje společnost Génomic Vision SA?
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company offers FiberVision, a molecular combing platform that helps in DNA analysis workflow; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision, a scanner that acquires high resolution images of the whole surface of the coverslip with a hands-off workflow; FiberStudio, a software, which detects hybridization signals and analyzes data to generate results and reporting; FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; and accessories, such as custom treated glass carriers and disposable DNA reservoirs for use with the MCS, as well as sample cartridges for scanners. It also provides FiberProbes for BRCA that is a set of Genomic Morse Codes for the detection of mutations occurring in hereditary breast and ovarian cancer; and hereditary nonpolyposis colorectal cancer Genomic Morse Code sets, which allows the identification and characterization of various structural variations, including anomalies occurring in flanking regions of the MMR genes. In addition, the company offers combing services that allow customers to validate the planned gene editing events; detect incorrect events larger than 1kb, including incorrect deletions, insertions, or inversions; and quantify off-target/on-target ratios. It has a strategic alliance with Quest Diagnostics; and development agreement with La Timone Hospital; research and development agreement with the Institut Pasteur. Genomic Vision Société Anonyme was founded in 2004 and is headquartered in Bagneux, France.
Firmy s metrikou budoucí p/e podobnou společnosti Génomic Vision SA
- Hodnota metriky Budoucí P/E společnosti Pulmatrix Inc je -0.34
- Hodnota metriky Budoucí P/E společnosti Brickell Biotech Inc je -0.34
- Hodnota metriky Budoucí P/E společnosti Unity Biotechnology Inc je -0.32
- Hodnota metriky Budoucí P/E společnosti SenesTech Inc je -0.31
- Hodnota metriky Budoucí P/E společnosti Bluebird bio Inc je -0.29
- Hodnota metriky Budoucí P/E společnosti Adlabs Entertainment je -0.27
- Hodnota metriky Budoucí P/E společnosti Génomic Vision SA je -0.27
- Hodnota metriky Budoucí P/E společnosti Acelrx Pharmaceuticals Inc je -0.27
- Hodnota metriky Budoucí P/E společnosti Tonix Pharmaceuticals Corp je -0.26
- Hodnota metriky Budoucí P/E společnosti SINTX Technologies Inc je -0.26
- Hodnota metriky Budoucí P/E společnosti MSP Steel & Power je -0.24
- Hodnota metriky Budoucí P/E společnosti Just Inc je -0.22
- Hodnota metriky Budoucí P/E společnosti Idea Cellular je -0.20